# Trump Administration Ready To Move Ahead On Marijuana Rescheduling > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/trump-administration-cannabis-rescheduling-update/ > **Published:** 2026-04-22T18:05:31-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:15:02-04:00 > **Clinical Summary:** Stay informed on the Trump administration cannabis rescheduling update and its impact on federal policy and clinical practice. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic PolicyRegulationFederal LawClinical PracticeAccess Why This Matters Federal rescheduling of cannabis could fundamentally alter clinical practice by removing DEA oversight of physician recommendations and potentially enabling interstate commerce of medical products. This would affect prescribing protocols, insurance coverage decisions, and research access for clinicians treating patients with [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/). Clinical Summary The Trump administration appears positioned to advance cannabis rescheduling from Schedule I to a lower classification, following the President’s executive order from months prior. Rescheduling would remove cannabis from the category of substances with ‘no accepted medical use,’ potentially allowing traditional prescription pathways and reducing federal-state legal conflicts. The timeline and specific schedule designation remain unclear, with implementation dependent on DEA and FDA regulatory processes. Dr. Caplan’s Take “I’ve been preparing for this shift for years because rescheduling will create both opportunities and complications — we’ll need new protocols for everything from dosing standardization to insurance prior authorizations. The real question isn’t if this happens, but whether we’ll have adequate clinical frameworks ready when it does.” Clinical Perspective 🧠 Clinicians should begin familiarizing themselves with traditional pharmaceutical regulations that may apply to rescheduled cannabis products. Patient access patterns will likely shift significantly, requiring updated consent processes and documentation standards. Monitor developments in your state [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) programs, as federal changes may alter local implementation requirements. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Trump%20Administration%20Ready%20To%20Move%20Ahead%20On%20Marijuana%20Rescheduling%2C%20Four%20Months%20...%20%40drcaplan&url=https%3A//www.marijuanamoment.net/trump-administration-ready-to-move-ahead-on-marijuana-rescheduling-four-months-after-presidents-executive-order-report-says/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.marijuanamoment.net/trump-administration-ready-to-move-ahead-on-marijuana-rescheduling-four-months-after-presidents-executive-order-report-says/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Trump%20Administration%20Ready%20To%20Move%20Ahead%20On%20Marijuana%20Rescheduling%2C%20Four%20Months%20...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.marijuanamoment.net/trump-administration-ready-to-move-ahead-on-marijuana-rescheduling-four-months-after-presidents-executive-order-report-says/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.marijuanamoment.net/trump-administration-ready-to-move-ahead-on-marijuana-rescheduling-four-months-after-presidents-executive-order-report-says/](https://www.marijuanamoment.net/trump-administration-ready-to-move-ahead-on-marijuana-rescheduling-four-months-after-presidents-executive-order-report-says/) Table of Contents - [FAQ](#FAQ)[What type of cannabis development does this article cover?](#What_type_of_cannabis_development_does_this_article_cover) - [What is the clinical relevance rating of this news?](#What_is_the_clinical_relevance_rating_of_this_news) - [What areas of cannabis policy does this cover?](#What_areas_of_cannabis_policy_does_this_cover) - [Who should pay attention to this cannabis news?](#Who_should_pay_attention_to_this_cannabis_news) - [Why is this cannabis news considered “emerging”?](#Why_is_this_cannabis_news_considered_8220emerging8221) - [Related](#Related) ## FAQ #### What type of cannabis development does this article cover? This article discusses policy and regulatory developments in cannabis at the federal level. It focuses on emerging findings or policy changes that have notable clinical interest for healthcare practitioners. #### What is the clinical relevance rating of this news? The article has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This means the findings or policy developments are worth monitoring closely by healthcare professionals. #### What areas of cannabis policy does this cover? The article covers multiple aspects including general policy changes, regulatory updates, federal law developments, and clinical practice implications. These interconnected areas all impact how cannabis can be used in medical settings. #### Who should pay attention to this cannabis news? Healthcare providers, particularly those involved in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) or considering cannabis treatments, should monitor these developments. The clinical practice tag suggests this has direct implications for [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-review/) and treatment protocols. #### Why is this cannabis news considered “emerging”? The article is marked as “New” and deals with emerging findings or policy developments. This indicates recent changes in the [cannabis regulatory landscape](https://cedclinic.com/cannabis-rescheduling-update-ag-bondi-hearing-status-report/) that may affect clinical practice and patient access to cannabis treatments. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Trump ready to move on cannabis rescheduling (Newsletter: April 23, 2026)](https://cedclinic.com/cannabis-federal-rescheduling-clinical-implications/) A detailed newsletter covering the latest updates on cannabis rescheduling efforts by the Trump administration. [Read the Newsletter](https://cedclinic.com/cannabis-federal-rescheduling-clinical-implications/) White House pushes imminent easing of controls on marijuana – The Washington Post Insights into the White House's plans to ease marijuana controls and the potential federal policy impact. Explore the Report [Trump administration reclassifies medical marijuana as Schedule III – Quartz](https://cedclinic.com/medical-marijuana-schedule-iii-regulatory-changes/) An analysis of the Trump administration's reclassification of [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) and its clinical significance. [Learn More](https://cedclinic.com/medical-marijuana-schedule-iii-regulatory-changes/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).